NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)
Preterm Infants
About this trial
This is an interventional treatment trial for Preterm Infants focused on measuring NRDS, nHFOV, nCPAP, preterm infants
Eligibility Criteria
Inclusion criteria:
(1)Gestational age (GA) is from 26 to 34 weeks; (2) diagnosis of RDS. The diagnosis of RDS will be based on clinical manifestations (tachypnea, nasal flaring and or grunting) and chest X-ray findings; (3) RDS Silverman score>5; (4) informed parental consent has been obtained.
Exclusion criteria
(1) severe RDS requiring early intubation according to the American Academy of Pediatrics guidelines for neonatal resuscitation7; (2)major congenital malformations or complex congenital heart disease; (3) group B hemolytic streptococcus pneumonia, septicemia, pneumothorax, pulmonary hemorrhage; (4) cardiopulmonary arrest needing prolonged resuscitation; (5) transferred out of the NICUs without treatment.
Sites / Locations
- Xingwang Zhu
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
nCPAP
nHFOV
nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS